as sequelae of intrauterine or perinatal brain injury, pyridoxine dependence, glucose transporter type 1 deficiency syndrome, neurocutaneous syndromes, some metabolic/degenerative disorders, and epileptic syndromes (table) . Hence the evaluation begins with a comprehensive history and examination to look for features of perinatal insult, dysmorphism (suggesting a chromosomal abnormality), and neurocutaneous markers. A brain MRI must be obtained to look for structural causes (e.g., malformations, sequelae of previous insults, features of tuberous sclerosis). Metabolic screening tests such as blood ammonia, arterial lactate, blood acylcarnitine profile, and urine organic acid studies are then performed to exclude organic acidemias, aminoacidopathies, and urea cycle defects. If all these investigations are normal, therapeutic trials of pyridoxine, pyridoxal phosphate, and folinic acid must be given sequentially. Another treatable metabolic cause of refractory infantile epilepsy is glucose transporter defect, which is diagnosed by the presence of CSF hypoglycorrhachia (CSF/blood sugar ratio Ͻ0.4). An EEG should be performed to look for localization of seizure focus, and for diagnosis of infantile epileptic encephalopathies such as Ohtahara syndrome and epilepsy of infancy with migrating focal seizures. Other rare causes of refractory infantile seizures include Alpers disease, some chromosomal abnormalities (e.g., ring chromosome 20), and SCN1A mutation-related epilepsy. 2, 3 CLINICAL CASE, PART II MRI of the brain, arterial blood gas, blood lactate and ammonia levels, urine ketones, plasma acylcarnitine profile, urine gas chromatography-mass spectrometry for organic acids, hair microscopy, serum copper and ceruloplasmin levels, thyroid profile, CSF examination (including glucose and lactate), and the karyotype were normal. The EEG revealed multifocal spikes and ictal rhythms arising variably from the right or left hemispheres (figure). The patient's seizures were uncontrolled despite treatment with sodium valproate, clobazam, pyridoxine, biotin, and folinic acid. The final diagnosis of epilepsy of infancy with migrating focal seizures was concluded based on the electroclinical findings and exclusion of known etiologies. When followed up at 16 months of age, he continued to have 1-2 seizures per week, severe psychomotor retardation, and a head circumference below the first percentile.
DISCUSSION Epilepsy of infancy with migrating focal seizures (earlier known as malignant migrating partial seizures in infancy) was first reported in 1995 by Coppola et al., who described 14 infants with a severe epileptic disorder characterized by refractory multifocal seizures involving both hemispheres and severe psychomotor developmental delay. 2 The diag- nostic criteria include the presence of 1) normal development before seizure onset, 2) onset before 6 months, 3) migrating focal motor seizures at onset, 4) multifocal seizures becoming intractable, 5) intractable to conventional antiepileptic drugs, 6) no identified etiology, and 7) profound psychomotor delay. 4 It is a rare syndrome and has been reported in approximately 50 patients.
Clinical features. Three distinct phases are described in the natural history of this syndrome. 4, 5 Seizures appear after an uneventful perinatal period and normal early development. The first phase is heralded by seizures beginning in the first few months. The seizures are mainly focal motor with frequent secondary generalization. Autonomic manifestations such as apnea, cyanosis, or flushing are common. This phase usually lasts a few weeks or months. The second phase (also called the stormy phase) starts variably between 1 and 12 months of age. It is characterized by very frequent polymorphous focal seizures. They occur in multiple clusters in a day or nearly continuously. Long-term video EEG recordings frequently reveal subclinical ictal manifestations during this phase. The third phase begins between 1 and 5 years of age. It is a relatively seizure-free period with severe psychomotor retardation. This phase may be frequently complicated by seizure recurrences during intercurrent illnesses and further developmental regression.
Etiology. The exact etiology of this syndrome is not known. A role of channelopathies or metabolic disorders is suspected and is the focus of ongoing research. Neuroimaging has been normal in all reported patients. No familial occurrence or consanguinity has been reported. No metabolic abnormalities have been identified. In those cases that were examined postmortem, no cortical dysplasia or neuronal migration defects have been found. 4 Sodium channel (SCN1A) mutations have been identified in patients with infantile-onset cryptogenic focal epilepsy with variable intellectual disabilities. 3 However, no mutations of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), or chloride (CLCN2) ion channels were identified in a study of 3 patients with epilepsy of infancy with migrating focal seizures. 6 Recently, a submicroscopic duplication 16p11.2 was found in an infant with this phenotype, raising the possibility that such chromosomal rearrangements may play an etiologic role.
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EEG. The EEG patterns in migrating partial seizures in infancy evolve over time. 8 The interictal EEG initially shows diffuse slowing of background activity and frequent slow waves, which often shift from one hemisphere to the other. Multifocal discharges originating from both hemispheres are also frequently noted. The ictal EEGs display paroxysmal discharges occurring in various regions in consecutive seizures in a given patient. The area of ictal onset shifts from one region to another and from one hemisphere to the other, with occasional overlapping of consecutive seizures. The migratory feature of ictal discharges is not pathognomonic of the disorder and may be seen in benign partial epilepsy of infancy. Treatment. Therapies including conventional antiepileptic drugs, pyridoxine, biotin, folinic acid, ketogenic diet, steroids, and adrenocorticotropic hormone have proved ineffective. Vigabatrin and carbamazepine may worsen the seizures. Some improvement has been reported with the use of bromides and stiripentol. Prognosis. The long-term outcome is dismal in most cases. Most children have severe psychomotor retardation and acquired microcephaly along with continuing seizures. A few children whose seizures are controlled may acquire the ability to reach for objects and walk, but do not develop language. A number of patients die before the end of the first year of age or later, mainly because of intercurrent infections and respiratory failure.
